Multiple sclerosis associated fatigue during natalizumab treatment

Journal of the Neurological Sciences

Volumn 285, Issue 1-2, 2009, Pages 109-113

  Putzki, Norman ^a,b   Yaldizli, Özgür ^b   Tettenborn, Barbara ^b   Diener, Hans Christoph ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

Fatigue; Multiple sclerosis; Natalizumab; Quality of life

Indexed keywords

GADOLINIUM; NATALIZUMAB;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; ENCEPHALITIS; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; COHORT STUDIES; FATIGUE; FEMALE; GADOLINIUM; HUMANS; IMMUNOLOGIC FACTORS; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROSPECTIVE STUDIES; QUESTIONNAIRES; RECURRENCE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 69549130717     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2009.06.004     Document Type: Article

References (38)

1. Krupp L.B., Alvarez L.A., LaRocca N.G., and Scheinberg L.C. Fatigue in multiple sclerosis. Arch Neurol 45 (1988) 435-437
2. Krupp L.B., LaRocca N.G., Muir-Nash J., and Steinberg A.D. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46 (1989) 1121-1123
3. Freal J.E., Kraft G.H., and Coryell J.K. Symptomatic fatigue in multiple sclerosis. Arch Phys Med Rehabil 65 (1984) 135-138
4. Fisk J.D., Pontrefact A., Ritvo P.G., et al. The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci 21 (1994) 9-14
5. Branas P., Jordan R., Fry-Smith A., Burls A., and Hyde C. Treatments for fatigue in multiple sclerosis: a rapid and systematic review. Health Technol Assess 4 (2000) 41-61
6. Stankoff B., Waubant E., Confavreux C., Edan G., Debouverie M., Rumbach L., et al. Modafinil for fatigue in MS. A randomized placebo-controlled double-blind study. Neurology 64 (2005) 1139-1143
7. Giovannoni G., Thompson A.J., Miller D.H., et al. Fatigue is not associated with raised inflammatory markers in multiple sclerosis. Neurology 57 (2001) 676-681
8. Heesen C., Nawrath L., Reich C., Bauer N., Schulz K.H., and Gold S.M. Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour?. J Neurol Neurosurg Psychiatry 77 (2006) 34-39
9. Flachenecker P., Bihler I., Weber F., Gottschalk M., Toyka K.V., and Rieckmann P. Cytokine mRNA expression in patients with multiple sclerosis and fatigue. Mult Scler 10 (2004) 165-169
10. Putzki N., Katsarava Z., Vago S., Diener H.C., and Limmroth V. Prevalence and severity of multiple sclerosis associated fatigue. Eur Neurol 59 (2008) 136-142
11. Metz L.M., Patten S.B., Archibald C.J., Bakker J.I., Harris C.J., Patry D.G., et al. The effect of immunomodulatory treatment on multiple sclerosis fatigue. J Neurol Neurosurg Psychiatry 75 (2004) 1045-1047
12. Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., Richer J.R., Salazar A.M., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol 39 (1996) 285-294
13. Bergamaschi R., Romani A., Versino M., Poli R., and Cosi V. Clinical aspects of fatigue in multiple sclerosis. Funct Neurol 12 (1997) 247-251
14. Colosimo C., et al. Fatigue in MS is associated with specific clinical feature. Acta Neurol Scand 92 (1995) 353-355
15. Polman C.H., O'Connor P.W., Havrdova E., et al. A randomized, placebo controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354 (2006) 899-910
16. Yousry T.A., Major E.O., Ryschkewitsch C., et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354 (2006) 924-933
17. Kappos L., Bates D., Hartung H.P., et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 6 (2007) 431-441
18. Rudick R.A., Miller D., Hass S., et al. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol 62 (2007) 335-346
19. Arnoldus J.A., Killestein J., Pfennings L.E.M.A., et al. Quality of life during the first 6 months of interferon-B treatment in patients with MS. Mult Scler 6 (2000) 338-342
20. Zivadinov R., Zorzon M., Tommasi M.A., et al. A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a. J Neurol Sci 216 (2003) 113-118
21. Vermersch P., Seze J., Delisse B., et al. Quality of life in multiple sclerosis: influence of interferon-beta1 a (Avonex) treatment. Mult Scler 8 (2002) 377-381
22. Schwartz C.E., Coulthard-Morris L., Cole B., and Vollmer T. The quality-of-life effects of interferon beta-1b in multiple sclerosis: an extended Q-TWIST analysis. Arch Neurol 54 (1997) 1475-1480
23. Krupp L.B., LaRocca N.G., Muir-Nash J., and Steinberg A.D. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46 (1989) 1121-1123
24. Bergamaschi R., Romani A., Versino M., et al. Clinical aspects of fatigue in multiple sclerosis. Funct Neurol 12 (1997) 247-251
25. Flachenecker P., Kümpfel T., Kallmann B., et al. Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameter. Mult Scler 8 (2002) 523-526
26. Beck A.T., Ward C.H., Medelson M., et al. An inventory for measuring depression. Arch Gen Psychiatry 4 (1961) 561-571
27. Wingerchuk D.M., Benarroch E.E., O'Brien P.C., et al. A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology 64 (2005) 1267-1269
28. Khademi M., Stol D., Olsson T., and Walström E. Induction of systemic TNF alpha in natalizumab-treated multiple sclerosis. Mult Scler 15 (2008) 309-312
29. Mainero C., Faroni J., Gasperini C., et al. Fatigue and magnetic resonance imaging activity in multiple sclerosis. J Neurol 246 (1999) 454-458
30. Filippi M., Rocca M.A., Colombo B., et al. Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis. Neuroimage 15 (2002) 559-567
31. Rocca M.A., Falini A., Colombo B., Scotti G., Comi G., and Filippi M. Adaptive functional changes in the cerebral cortex of patients with nondisabling multiple sclerosis correlate with the extent of brain structural damage. Ann Neurol 51 (2002) 330-339
32. Roelcke U., Kappos L., and Lechner-Scott J. Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology 48 (1997) 1566-1571
33. Janardhan V., and Bakshi R. Quality of life and it's relationship to brain lesions and atrophy on magnetic resonance images in 60 patients with multiple sclerosis. Arch Intern Med 57 (2000) 1485-1491
34. Montel S.R., and Bungener C. Coping and quality of life in one hundred and thirty five subjects with multiple sclerosis. Mult. Scler. 13 (2007) 393-401
35. Kobelt G., Berg J., Lindgren P., Fredrikson S., and Jönsson B. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 77 (2006) 918-926
36. Lily O., McFadden E., Hensor E., Johnson M., and Ford H. Disease-specific quality of life in multiple sclerosis: the effect of disease modifying treatment. Mult. Scler. 12 (2006) 808-813
37. Miltenburger C., and Kobelt G. Quality of life and cost of multiple sclerosis. Clin Neurol Neurosurg 104 (2002) 272-275
38. Tellez N., Rio J., Tintore M., Nos C., Galan I., and Montalban X. Fatigue in multiple sclerosis persists over time. A longitudinal study. J Neurol 253 (2006) 1466-1470